|
KMID : 1146320130010010051
|
|
Journal of Health Technology Assessment
2013 Volume.1 No. 1 p.51 ~ p.60
|
|
|
Risk Sharing Agreements on Pharmaceuticals: Lessons from Foreign Countries’ Experience
|
|
Cheong Che-Lim
Lee Tae-Jin
Kim Sun
Son Kyung-Bok
Bae Eun-Young
|
|
|
Abstract
|
|
|
Objectives: To examine experiences of risk sharing agreements (RSAs) on pharmaceuticals from foreign countries and to identify advantages and disadvantages of various types of RSAs in order to draw insights for domestic implementation.
Methods: Based on a comprehensive search for relevant information on RSA practices, we examined and compared different experiences of RSAs on pharmaceuticals in the following seven countries: the United Kingdom, Italy, France, Germany, Australia, the United States, and Canada.
Results: In all countries examined, the number and range of RSAs has been grown including orphan drugs and at least one type of population level RSAs such as price-volume agreements, price change, and expenditure cap schemes were implemented as statutory procedures.
Conclusion: Regarding domestic pharmaceutical policies, non-outcome based population level RSAs are more appropriate rather than patient level agreements because of administrative burdens such as outcome measurement and information system development.
|
|
|
KEYWORD
|
|
|
Risk sharing, financial, Economics, pharmaceutical, Insurance coverage
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|